Rare diseases
Investigational molecules
Locations
Clinical trials in Lithuania – page 21245 clinical trials in Lithuania across 6 research sites in 10 cities. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in LithuaniaKlinikiniai-Tyrimai.lt(opens in a new tab)LithuaniaLithuaniaLithuaniaLithuaniaLithuaniaWhere most of the country's trials are run
Shares are of these cities' trials together.
10 cities, A–Z – pick yours to filter the trials
What the registry says about research in the country
Clinical research in Lithuania encompasses a broad spectrum of cardiovascular conditions, focusing on improving outcomes for patients with heart failure, acute coronary syndrome, and atherosclerotic cardiovascular disease. Trials investigate novel therapies for individuals with reduced, mildly reduced, or preserved ejection fraction, often examining the role of systemic inflammation in disease progression. Studies also address atrial fibrillation, evaluating anticoagulation strategies to prevent stroke and systemic embolism, as well as interventions following acute myocardial infarction to reduce recurrent cardiovascular events.
Research efforts aim to demonstrate superiority or non-inferiority of emerging treatments compared to standard care, with a focus on reducing major adverse cardiovascular events and improving quality of life for patients across different stages of disease.
The country's oncology research landscape covers a wide array of malignancies, including non-small cell lung cancer, melanoma, acute myeloid leukemia, and various solid tumors. Trials evaluate both immunotherapy and targeted therapy approaches, often in combination with chemotherapy or radiation. Studies investigate treatment strategies for newly diagnosed patients, as well as those with relapsed or refractory disease, spanning early-stage resectable cancers to advanced metastatic conditions.
These investigations assess progression-free survival, overall survival, and objective response rates, aiming to establish more effective treatment regimens and improve long-term outcomes for cancer patients.
Research into autoimmune diseases represents a significant focus, with trials examining conditions such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, and ulcerative colitis. Studies evaluate novel biologics and small molecules targeting specific inflammatory pathways, often comparing them to placebo or active comparators. The research addresses patients with moderate to severe disease who have inadequate responses to conventional therapies.
These trials measure clinical remission, endoscopic response, and reduction in disease activity scores, seeking to identify treatments that can induce sustained remission and reduce the need for corticosteroids.
Clinical trials in neurology address diverse conditions including multiple sclerosis, epilepsy, and acute ischemic stroke. Research on relapsing multiple sclerosis evaluates disease-modifying therapies aimed at reducing relapse rates and delaying disability progression. Studies in epilepsy investigate adjunctive treatments for focal onset seizures and refractory status epilepticus, while stroke trials focus on prevention strategies following acute events.
These investigations assess annualized relapse rates, time to disability progression, seizure frequency reduction, and prevention of recurrent cerebrovascular events, contributing to improved neurological care.
Renal research encompasses chronic kidney disease, IgA nephropathy, lupus nephritis, and conditions such as C3 glomerulopathy. Trials evaluate interventions to reduce proteinuria, preserve renal function, and address complications including anemia associated with chronic kidney disease. Studies also investigate treatments for patients with end-stage kidney disease undergoing dialysis, focusing on reducing systemic inflammation and cardiovascular risk.
The research aims to demonstrate efficacy in preserving kidney function, reducing proteinuria levels, and managing complications, ultimately improving outcomes for patients with progressive renal disease.
Respiratory research focuses on chronic obstructive pulmonary disease, asthma, and pulmonary arterial hypertension. Trials evaluate bronchodilators, anti-inflammatory agents, and targeted therapies for patients with moderate to severe disease. Studies in severe eosinophilic asthma investigate biologics targeting specific inflammatory pathways, while research in pulmonary arterial hypertension assesses treatments aimed at improving exercise capacity and hemodynamics.
These trials measure improvements in lung function, symptom control, exercise capacity, and quality of life, seeking to establish more effective management strategies for chronic respiratory conditions.
Research in hematology addresses conditions including hemophilia, paroxysmal nocturnal hemoglobinuria, immune thrombocytopenic purpura, and myelodysplastic syndromes. Trials evaluate novel factor replacement therapies, complement inhibitors, and agents targeting anemia in myelodysplastic syndromes. Studies investigate both acute and chronic hematologic conditions, with focus on reducing bleeding episodes, transfusion requirements, and disease progression.
The investigations aim to demonstrate improvements in bleeding control, hemoglobin levels, transfusion independence, and overall quality of life for patients with these challenging hematologic conditions.
Clinical trials address type 2 diabetes, hypertriglyceridemia, and congenital adrenal hyperplasia. Research evaluates glucose-lowering therapies, lipid-modifying agents for severe hypertriglyceridemia, and treatments to reduce glucocorticoid requirements in congenital adrenal hyperplasia. Studies also investigate acromegaly and other hormonal disorders, focusing on normalizing hormone levels and reducing disease-related complications.
These trials measure glycemic control, lipid levels, hormone normalization, and reduction in glucocorticoid doses, contributing to improved metabolic management and reduced long-term complications.
Research in ophthalmology focuses on neovascular age-related macular degeneration and macular edema secondary to retinal vein occlusion. Trials evaluate anti-vascular endothelial growth factor therapies with varying dosing regimens, assessing visual acuity outcomes and anatomic changes in the retina. Studies compare different treatment frequencies and doses to optimize therapeutic benefit while minimizing treatment burden.
The investigations aim to demonstrate non-inferiority or superiority of extended dosing intervals, measuring best-corrected visual acuity changes and retinal thickness, ultimately seeking to improve convenience without compromising efficacy.
Dermatology research addresses atopic dermatitis, psoriatic arthritis, chronic urticaria, and hidradenitis suppurativa. Trials evaluate targeted immunomodulatory therapies for patients with moderate to severe disease who have inadequate responses to conventional treatments. Studies investigate biologics and small molecules that target specific inflammatory mediators, measuring clinical response, symptom control, and quality of life improvements.
These investigations assess skin clearance, reduction in disease activity, and improvements in patient-reported outcomes, seeking to establish more effective long-term management strategies for chronic inflammatory skin conditions.
Research in infectious diseases evaluates novel antibiotics for complicated urinary tract infections, diabetic foot infections, and community-acquired pneumonia. Trials compare new antimicrobial agents to standard therapies, assessing clinical response rates and safety profiles. Studies also address COVID-19 and investigate treatments for bacterial skin and skin structure infections, focusing on efficacy against resistant organisms.
These trials measure clinical cure rates, microbiological eradication, and safety outcomes, contributing to the development of effective treatments for serious bacterial infections in an era of increasing antimicrobial resistance.
Research encompasses primary biliary cholangitis, acute-on-chronic liver failure, and erosive esophagitis. Trials evaluate therapies aimed at reducing disease progression, improving survival, and managing complications in patients with chronic liver disease. Studies investigate novel cellular therapies and pharmacologic interventions, measuring biochemical markers, survival rates, and clinical outcomes in critically ill patients with liver failure.
These investigations assess overall survival, biochemical response, and reduction in organ failures, seeking to improve outcomes for patients with advanced liver disease and associated complications.
Clinical trials address systemic sclerosis, Sjögren's syndrome, axial spondyloarthritis, and gout. Research evaluates disease-modifying therapies, biologics, and urate-lowering agents for patients with inadequate responses to conventional treatments. Studies investigate novel mechanisms of action targeting specific inflammatory pathways, measuring disease activity scores, functional outcomes, and biomarkers of disease progression.
These trials assess improvements in disease activity, functional capacity, and achievement of therapeutic targets such as serum urate levels, contributing to better management of chronic rheumatologic conditions.
Pediatric research focuses on juvenile idiopathic arthritis, growth disorders, pediatric acute lymphoblastic leukemia, and pulmonary arterial hypertension in children. Trials evaluate treatment strategies for children with short stature, investigate optimal therapy withdrawal timing in juvenile arthritis patients achieving remission, and assess novel agents for pediatric malignancies. Studies also address iron deficiency anemia in children with chronic kidney disease.
These investigations measure growth velocity, disease remission rates, event-free survival, and exercise capacity, aiming to optimize treatment approaches while minimizing long-term medication exposure in the pediatric population.
Research in urology addresses prostate cancer, neurogenic detrusor overactivity, and non-muscle invasive bladder cancer. Trials evaluate hormonal therapies, combination treatments, and novel agents for advanced prostate cancer, including metastatic hormone-sensitive and castration-resistant disease. Studies also investigate treatments for urinary dysfunction and bladder cancer, measuring progression-free survival, radiographic progression-free survival, and symptom control.
These trials aim to demonstrate improvements in survival outcomes, delay disease progression, and enhance quality of life for patients with urologic malignancies and functional disorders.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
